Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia

Clinical Microbiology and Infection

Volumn 18, Issue 4, 2012, Pages

  Teh, B ^a   Grayson, M L ^a,b,c   Johnson, P D R ^a,c   Charles, P G P ^a,c  

^a AUSTIN HEALTH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Community acquired pneumonia; Doxycycline; Macrolides; Outcomes

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; MACROLIDE; ROXITHROMYCIN;

ANTIBIOTIC THERAPY; COMMUNITY ACQUIRED PNEUMONIA; DEMOGRAPHY; DISEASE SEVERITY; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MONOTHERAPY; MORTALITY; MYCOPLASMA; NOTE; OUTCOME ASSESSMENT; PNEUMONIA SEVERITY INDEX; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANK SUM TEST; STREPTOCOCCUS PNEUMONIAE; STUDENT T TEST;

BACTERIA (MICROORGANISMS); CHLAMYDOPHILA; LEGIONELLA; MYCOPLASMA;

EID: 84858709708     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03759.x     Document Type: Article

References (15)

1. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl 2): S27-S72.
2. Woodhead M, Blasi F, Ewig S et al. Joint Taskforce of the European respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infec 2011; 17 (Suppl 6): E1-E59.
3. Peuchant O, Ménard A, Renaudin H et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother 2009; 64: 52-58.
4. Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis 2009; 15: 1260-1264.
5. Charles PG, Whitby M, Fuller AJ et al. The aetiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis 2008; 46: 1513-1521.
6. Antibiotic Expert Group. Therapeutic guidelines: antibiotic. 14th edn. North Melbourne, Australia: Therapeutic Guidelines Limited, 2010.
7. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
8. Oosterheert JJ, Bonten MJ, Hak E et al. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review J Antimicrob Chemother 2003; 52: 555-563.
9. Martinez FJ. Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients. Clin Infect Dis 2004; 38 (Suppl 4): S328-S340.
10. Amsden GW. Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55: 10-21.
11. Jones RN, Sader HS, Fritsche TR. Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002). Diagn Microbiol Infect Dis 2004; 49: 147-149.
12. Eisen DP. Doxycycline. In: Grayson ML. Lead editor. Kucers' the use of antibiotics. 6th edn. London, United Kingdom: ASM press, 2010. 851-869.
13. Stewardson A, Grayson ML. Psittacosis. Infect Dis Clin North Am 2010; 24: 7-25.
14. Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother 2010; 16: 78-86.
15. Cao B, Zhao CJ, Yin YD et al. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin Infect Dis 2010; 51: 189-194.